Cargando…

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

OBJECTIVE: To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. METHODS: Multicenter prospective study including 57 RRMS patients tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walo-Delgado, Paulette Esperanza, Monreal, Enric, Medina, Silvia, Quintana, Ester, Sainz de la Maza, Susana, Fernández-Velasco, José Ignacio, Lapuente, Paloma, Comabella, Manuel, Ramió-Torrentà, Lluis, Montalban, Xavier, Midaglia, Luciana, Villarrubia, Noelia, Carrasco-Sayalero, Angela, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Meca-Lallana, José, Alvarez-Lafuente, Roberto, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531491/ https://www.ncbi.nlm.nih.gov/pubmed/34691084 http://dx.doi.org/10.3389/fimmu.2021.760546

Ejemplares similares

Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
por: Monreal, Enric, et al.
Publicado: (2021)

Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
por: Walo-Delgado, Paulette Esperanza, et al.
Publicado: (2021)

Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
por: Rodero-Romero, Alexander, et al.
Publicado: (2023)

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
por: Fernández-Velasco, José I., et al.
Publicado: (2021)

Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
por: Fernández-Velasco, José I., et al.
Publicado: (2022)

Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
por: Picón, Carmen, et al.
Publicado: (2021)

Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients
por: Medina, Silvia, et al.
Publicado: (2019)

Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis
por: Monreal, Enric, et al.
Publicado: (2023)

High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
por: Monreal, Enric, et al.
Publicado: (2020)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
por: Fernández, Óscar, et al.
Publicado: (2023)

XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
por: Fernández, Óscar, et al.
Publicado: (2023)

Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat(®) Methodology
por: Fernandez, Oscar, et al.
Publicado: (2021)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
por: Meca-Lallana, J. E., et al.
Publicado: (2021)

Cognitive Dysfunctions and Assessments in Multiple Sclerosis
por: Oreja-Guevara, Celia, et al.
Publicado: (2019)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
por: Domínguez-Mozo, María Inmaculada, et al.
Publicado: (2023)

The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms
por: Fernández, Óscar, et al.
Publicado: (2020)

Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19
por: Monreal, Enric, et al.
Publicado: (2020)

Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
por: Meca-Lallana, José E., et al.
Publicado: (2021)

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial
por: Villoslada, Pablo, et al.
Publicado: (2015)

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
por: Meca-Lallana, Jose E, et al.
Publicado: (2021)

Anti-NMDA receptor encephalitis secondary to SARS-CoV-2 infection
por: Alvarez Bravo, G., et al.
Publicado: (2020)

Encefalitis anti-NMDA-R secundaria a infección por SARS-CoV-2
por: Álvarez Bravo, G., et al.
Publicado: (2020)

Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non‐cell‐autonomous neuronal damage
por: Matute‐Blanch, Clara, et al.
Publicado: (2022)

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
por: Camacho-Toledano, Celia, et al.
Publicado: (2022)

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
por: Lopez-Soley, Elisabet, et al.
Publicado: (2022)

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
por: Sepúlveda, Maria, et al.
Publicado: (2016)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Clinical and radiological features of cerebral amyloid angiopathy-related inflammation
por: Bravo, Gary Álvarez, et al.
Publicado: (2021)

Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression
por: Pérez-Pérez, Silvia, et al.
Publicado: (2021)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_60te773u147j2120i3n6mhbsps